國立高雄大學圖資館 |

Language: English

Back

Cancer II

SpringerLink (Online service)

Cancer II

Record Type:	Electronic resources : Monograph/item
Title/Author:	Cancer IIedited by Michael J. Waring.
other author:	Waring, Michael J.
Published:	Cham :Springer International Publishing :2018.
Description:	xiv, 475 p. :ill. (some col.), digital ;24 cm.
Contained By:	Springer eBooks
Subject:	CancerChemotherapy.
Online resource:	https://doi.org/10.1007/978-3-319-75926-5
ISBN:	9783319759265$q(electronic bk.)

Cancer II
Cancer II[electronic resource] /edited by Michael J. Waring. - Cham :Springer International Publishing :2018. - xiv, 475 p. :ill. (some col.), digital ;24 cm. - Topics in medicinal chemistry,281862-2461 ;. - Topics in medicinal chemistry ;8..

Progress in the Discovery of BCR-ABL Kinase Inhibitors for the Treatment of Leukemia -- Small Molecule Inhibitors of the Epidermal Growth Factor Receptor -- Small-Molecule Inhibitors of Bruton's Tyrosine Kinase -- Inhibitors of Vascular Endothelial Growth Factor Receptor -- Inhibitors of the Fibroblast Growth Factor Receptor -- Modulation of the DNA-Damage Response by Inhibitors of the Phosphatidylinositol 3-Kinase Related Kinase (PIKK) Family -- Epigenetic Modulators -- Antibody–Drug Conjugates -- Isoform Selective PI3K Inhibitors for Treating Cancer -- Inhibitors of the Kynurenine Pathway -- Protein–Protein Interaction Inhibitors -- Small Molecule Inhibitors of ALK.

This book reviews recent breakthroughs in anti-cancer drug discovery. Building on the previous volume in the series, it outlines some of the most significant developments that have occurred in the field in the subsequent period that have led to new drug approvals or promising clinical candidates. The volume is divided into chapters that each relate to a specific protein or protein class. Each chapter provides an overview of the underlying biology and then emphasises the medicinal chemistry strategies and tactics that led to the most significant drugs and drug candidates. A summary of clinical data and the future outlook for the field is also provided. Each chapter is authored by experts in the topic and who have themselves made significant contributions to their respective fields.

ISBN: 9783319759265$q(electronic bk.)

Standard No.: 10.1007/978-3-319-75926-5doiSubjects--Topical Terms:

194707
Cancer
--Chemotherapy.

LC Class. No.: RC271.C5 / C363 2018

Dewey Class. No.: 616.994061

Cancer II
LDR:02493nmm a2200337 a 4500 001 548274
003 DE-He213
005 20190515132647.0
006 m d
007 cr nn 008maaau
008 190729s2018 gw s 0 eng d
020 $a 9783319759265$q(electronic bk.)
020 $a 9783319759241$q(paper)
024 7 $a 10.1007/978-3-319-75926-5 $2 doi
035 $a 978-3-319-75926-5
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.C5 $b C363 2018
072 7 $a PSB $2 bicssc
072 7 $a SCI013020 $2 bisacsh
072 7 $a PSB $2 thema
082 0 4 $a 616.994061 $2 23
090 $a RC271.C5 $b C215 2018
245 0 0 $a Cancer II $h [electronic resource] / $c edited by Michael J. Waring.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a xiv, 475 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a Topics in medicinal chemistry, $x 1862-2461 ; $v 28
505 0 $a Progress in the Discovery of BCR-ABL Kinase Inhibitors for the Treatment of Leukemia -- Small Molecule Inhibitors of the Epidermal Growth Factor Receptor -- Small-Molecule Inhibitors of Bruton's Tyrosine Kinase -- Inhibitors of Vascular Endothelial Growth Factor Receptor -- Inhibitors of the Fibroblast Growth Factor Receptor -- Modulation of the DNA-Damage Response by Inhibitors of the Phosphatidylinositol 3-Kinase Related Kinase (PIKK) Family -- Epigenetic Modulators -- Antibody–Drug Conjugates -- Isoform Selective PI3K Inhibitors for Treating Cancer -- Inhibitors of the Kynurenine Pathway -- Protein–Protein Interaction Inhibitors -- Small Molecule Inhibitors of ALK.
520 $a This book reviews recent breakthroughs in anti-cancer drug discovery. Building on the previous volume in the series, it outlines some of the most significant developments that have occurred in the field in the subsequent period that have led to new drug approvals or promising clinical candidates. The volume is divided into chapters that each relate to a specific protein or protein class. Each chapter provides an overview of the underlying biology and then emphasises the medicinal chemistry strategies and tactics that led to the most significant drugs and drug candidates. A summary of clinical data and the future outlook for the field is also provided. Each chapter is authored by experts in the topic and who have themselves made significant contributions to their respective fields.
650 0 $a Cancer $x Chemotherapy. $3 194707
650 0 $a Drug development. $3 190608
650 1 4 $a Medicinal Chemistry. $3 275183
650 2 4 $a Cancer Research. $3 273660
650 2 4 $a Medical Biochemistry. $3 274286
700 1 $a Waring, Michael J. $3 228207
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
830 0 $a Topics in medicinal chemistry ; $v 8. $3 567153
856 4 0 $u https://doi.org/10.1007/978-3-319-75926-5
950 $a Chemistry and Materials Science (Springer-11644)